These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 12404884

  • 1. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M, Sologuren A, Valiente R, Smith J.
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [Abstract] [Full Text] [Related]

  • 2. Betamethasone does not prevent nausea and vomiting induced by ipecacuanha.
    Axelsson P, Thörn SE, Wattwil M.
    Acta Anaesthesiol Scand; 2004 Nov; 48(10):1283-6. PubMed ID: 15504189
    [Abstract] [Full Text] [Related]

  • 3. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
    Yamakuni H, Sawai H, Maeda Y, Imazumi K, Sakuma H, Matsuo M, Mutoh S, Seki J.
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
    [Abstract] [Full Text] [Related]

  • 4. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
    Jeremić B.
    Srp Arh Celok Lek; 1996 Mar; 124(5-6):131-4. PubMed ID: 9102832
    [Abstract] [Full Text] [Related]

  • 5. Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
    Martin C, Roman V, Agay D, Fatôme M.
    Radiat Res; 1998 Jun; 149(6):631-6. PubMed ID: 9611102
    [Abstract] [Full Text] [Related]

  • 6. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M, Blower P.
    Cancer; 2005 Jul 01; 104(1):1-18. PubMed ID: 15929119
    [Abstract] [Full Text] [Related]

  • 7. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer.
    Calvo R, Jiménez RM, Trocóniz IF, Suárez E, Gonzalo A, Lucero ML, Raczka E, Orjales A.
    Cancer Chemother Pharmacol; 1998 Jul 01; 42(5):418-22. PubMed ID: 9771958
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP, Fisher SG, Kiley K, Fletcher-Gonzalez D, Porter N, Stiff P.
    Biol Blood Marrow Transplant; 2001 Jul 01; 7(11):596-603. PubMed ID: 11760147
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Single-dose, placebo-controlled, phase I study of oral dolasetron.
    Dixon RM, Cramer M, Shah AK, Whitmore J, Benedict CR, Hahne WF.
    Pharmacotherapy; 1996 Jul 01; 16(2):245-52. PubMed ID: 8820468
    [Abstract] [Full Text] [Related]

  • 13. Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist.
    Ozaki A, Sukamoto T.
    Gen Pharmacol; 1999 Sep 01; 33(3):283-8. PubMed ID: 10480662
    [Abstract] [Full Text] [Related]

  • 14. 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
    King GL, Rabin BM, Weatherspoon JK.
    Aviat Space Environ Med; 1999 May 01; 70(5):485-92. PubMed ID: 10332945
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, Fitts D.
    Cancer J Sci Am; 1996 May 01; 2(2):85-90. PubMed ID: 9166505
    [Abstract] [Full Text] [Related]

  • 16. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
    Martoni A, Piana E, Strocchi E, Angelelli B, Guaraldi M, Zamagni C, Camaggi CM, Pannuti F.
    Anticancer Res; 1998 May 01; 18(4B):2799-803. PubMed ID: 9713464
    [Abstract] [Full Text] [Related]

  • 17. Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
    Minton NA.
    Br J Clin Pharmacol; 1994 Jun 01; 37(6):525-30. PubMed ID: 7917768
    [Abstract] [Full Text] [Related]

  • 18. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
    Endo T, Sugawara J, Nemoto M, Minami M, Blower PR.
    Res Commun Mol Pathol Pharmacol; 1998 Dec 01; 102(3):227-39. PubMed ID: 10342910
    [Abstract] [Full Text] [Related]

  • 19. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet.
    Grélot L, Le Stunff H, Milano S, Blower PR, Romain D.
    J Pharmacol Exp Ther; 1996 Oct 01; 279(1):255-61. PubMed ID: 8859001
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.